Global antibody drug conjugate market seen reaching $32.66 billion by 2035

The global antibody drug conjugate (ADC) market size is calculated at USD 14.76 billion in 2026 and is expected to reach around USD 32.66 billion by 2035, growing at a CAGR of 9.23% for the forecasted period. North America dominated the market with the largest revenue share by 53% in 2025, while Asia Pacific is expected to grow at the fastest rate during the forecast period.

The Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research published clinical pharmacology considerations or guidance for industries and experts working on antibody-drug conjugates. It addresses the thinking of the U.S. Food and Drug Administration (FDA) for bioanalytical methods, dose-and exposure-response analysis, dosing strategies, immunogenicity, intrinsic factors, QTc assessments, and drug-drug interactions. Antibody drug conjugates are described as a rapidly emerging class of therapeutic agents that are evolving with advancements in drug engineering and novel biologic insights.

By application, the breast cancer segment generated the biggest revenue share in 2025, and the blood cancer segment is expected to grow at the fastest rate during the forecast period. By product, the kadcyla segment held the largest share of the market in 2025, while the enhertu segment is estimated to grow at the fastest CAGR during 2026-2035. By target, the HER2 or human epidermal growth factor receptor 2 segment held the largest market share in 2025, and the CD22 segment is anticipated to grow at the fastest rate during the forecast period. By technology, the cleavable linker segment is expected to hold a major revenue share in 2025.

North America dominated the market share in 2025 owing to regulatory support from the U.S. FDA to offer approval pathways and innovative therapy designations, and technological advancements in next-generation antibody drug conjugate technologies. Strategic government-led initiatives aim to boost innovations in the oncology sector, and governments in the U.S. and Canada have launched initiatives to boost the development and standardisation of antibody drug conjugates.

The antibody drug conjugate market in the U.S. witnessed a leading position due to highly supportive regulatory pathways and the integration of AI that boosts biomarker discovery, target identification, and reduces R&D costs. Government-led programs are driven by advanced research programs and new clinical trial frameworks that aim to boost drug discovery and regulatory approval.

Asia Pacific is expected to grow at the fastest rate due to significant investments in biopharmaceutical infrastructure, increasing cancer burden, and supportive government policies that foster biopharma innovation. Government initiatives and high-value licensing deals aim to establish regional hubs for innovative drug development, including the National Bio Committee of South Korea, the 10-year government fund of Japan, the Research, Innovation, and Enterprise (RIE) plan of Singapore, and the innovative drug pilot plan of China.